A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
Completed
- Conditions
- Bronchial Asthma
- Registration Number
- NCT00505388
- Lead Sponsor
- AstraZeneca
- Brief Summary
This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5137
Inclusion Criteria
- Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme
- signed and dated informed consent(ICF)
- for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required
Read More
Exclusion Criteria
- Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇬🇧Welingborough, United Kingdom